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ToxicityAbstract Objective: Olanzapine is a second generation antipsychotic acting mainly as a dopamine
D2 and serotonine 5-HT2 receptors antagonist prescribed in the treatment of schizophrenia and var-
ious other psychiatric illnesses. Even though olanzapine is widely used in psychiatry, its effects on
the architecture of pancreas, liver and kidneys are little known. The histology of pancreas especially
has never been studied. For these reasons, the current study was designed to elucidate the toxic
effects of chronic administration of olanzapine on pancreas, liver and kidneys and the enzymes
released by these tissues in an escalating dose manner. Methods: Fourteen male rats were divided
into two groups equally, the olanzapine group and the controls. Olanzapine was administered in
a dose of 5 mg/kg/d for the ﬁrst eight weeks, 10 mg/kg/d for next four weeks and 15 mg/kg/d
through the last two week period of 14 weeks experiment. The controls received acidiﬁed saline
only. Both the groups received restricted diet (20 g/12 h). The body weight and level of random
blood sugar (RBS) were measured on a weekly basis. The levels of lipase, amylase, alanine transam-
inase (ALT) and aspartate transaminase (AST) were determined terminally. At the end of the exper-
iment, the tissues were dissected out for histopathological evaluation. Results: Signiﬁcant loss in
body weight, change in the level of random blood sugar (**P< 0.05, ***P< 0.001) and signiﬁcant
rise in amylase and lipase levels (*P< 0.05, ***P< 0.001) were observed. However, the same treat-
ment has shown no signiﬁcant change in the levels of alanine and aspartate transaminases92 091
Olanzapine induced biochemical and histopathological changes 699(P> 0.05). The pancreas has shown derangement of beta cells and ﬁbrotic growth. A mild to mod-
erate focal increase in glomerular cellularity, cellular proliferation and glomerular capsules with
negligible basement membranes were observed in the kidneys. No changes were observed in the
architecture of the liver. Conclusion: The ﬁndings of this study indicated that the incidence of
adverse effects associated with olanzapine could be prevented/alleviated/delayed by allowing
restricted diet.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Olanzapine is an atypical antipsychotic which is commonly
used in the treatment of schizophrenia and bipolar disorders.
Numerous studies have found that metabolic syndrome is
highly prevalent in schizophrenic patients on olanzapine ther-
apy than in general population (Houseknecht et al., 2006).
These metabolic events observed in the patients include weight
gain, dyslipidemia, insulin resistance and hyperglycemia mir-
roring impaired glucose metabolism (Houseknecht et al.,
2006). Olanzapine has been reported to have strong associa-
tion with new onset diabetes (Liebzeit et al., 2001). Weight
gain is one of the risk factors of diabetes, except a few reports
where diabetes did occur without any weight gain in patients
subjected to olanzapine. Discontinuation of antipsychotic
drugs (APDs) has been observed to decrease the plasma glu-
cose level (Kohen et al., 2008; Koller et al., 2003a; Waage
et al., 2004; Wirshing et al., 1998). It has also been shown in
animal models that the APDs cause hyperphagia, which results
in weight gain followed by hyperglycemia (Cope et al., 2005).
Olanzapine-induced acute pancreatitis was ﬁrst of all reported
in 2000 (Doucette et al., 2000). Food and Drug
Administration’s MedWatch Surveillance System and pub-
lished reports have indicated one hundred and ninety-two
patients with pancreatitis receiving one or the other antipsy-
chotic, with 33% due to olanzapine only (Koller et al.,
2003b; Waage et al., 2004). To the best of our knowledge,
no study on olanzapine-induced pancreatitis and olanzapine
induced changes in the architecture of pancreas has been
reported so far in rats. Pae and his colleagues have reported
elevation of liver enzymes in rats treated with olanzapine (2
and 4 mg/kg/d, i.p) for 6 weeks but the general architecture
of liver has been reported unaffected (Pae et al., 2005), con-
cluding it as damage to hepatocytes at cellular level.
Nephrotoxicity with chronic administration (6 weeks) of
olanzapine (0.5 and 2.5 mg/kg/d) has been reported with pos-
tulation that it was due to oxidative stress (Mustafa et al.,
2012). Dietary and pharmacological interventions have been
recommended to lessen the APDs-associated alarming events
with the suggestion to study the impact of APDs on body
weight by gradually escalating the dose (Gohlke et al., 2012).
The underlying mechanism of olanzapine-induced pathological
changes has been an issue of great concern among the scientiﬁc
community, but no or insufﬁcient data exist about the correla-
tion of biochemical and histopathological changes. The cur-
rent study was therefore designed to assess the effects of
chronic (4 months) oral administration of gradually increasing
doses of olanzapine on blood glucose, ALT, AST, amylase,
lipase and body weight in correlation with its effects on thearchitecture of pancreas, liver and kidneys while allowing
restricted diet.
2. Methods and materials
2.1. Animals
Sprague–dawley male rats were bred in animal house, depart-
ment of pharmacy, University of Peshawar. Total 14 animals,
weighing 160–300 g, were housed in plastic cages at a con-
trolled climate (19–23 C). The rats were maintained on 12 h
reversed light–dark cycle (light on between 21:00 and 9:00 h),
started 2 weeks before the start of dosing, and were handled
gently and carefully so that the animals were acclimatized
for experimental conditions. The animals were then equally
stratiﬁed into 2 groups, the olanzapine treated group and the
controls, each comprising of 7 animals. They were having free
access to water and measured quantity of food (20 g/12 h/
animal) (Pouzet et al., 2003). All the procedures were approved
from the Departmental Ethical Committee (Reference number,
02/EC-14/Pharm) and were in strict accordance with Animals
Scientiﬁc Procedures Act, 1986, UK.
2.2. Procedures
2.2.1. Drugs treatment
The animals were kept fasted for 24 h before ﬁrst dose was
administered. Olanzapine was formulated by dissolving it in
small quantity of 0.1 N acetic acid followed by volume make-
up with normal saline in a ratio of 1–100 (Pouzet et al., 2003).
Olanzapine was used in once daily doses of 5 mg/kg/d (Pouzet
et al., 2003) for ﬁrst 8 weeks, 10 mg/kg/d for next 4 weeks
(Andreasen et al., 1995; Pouzet et al., 2003) and 15 mg/kg/d
for last 2 weeks (Angelucci et al., 2005). Controls were adminis-
tered acidiﬁed normal saline in a volume based on body weight
(not greater than 5 ml/kg/d) (Pouzet et al., 2003). Both
olanzapine and saline freshly prepared were administered orally
by oral gavage method during the same period daily (07:00–
09:00) (Pouzet et al., 2003; Terry et al., 2003).
2.2.2. Random blood sugar
Random Blood Sugar was measured before the administration
of the ﬁrst dose and then weekly, using Abbott Glucometer.
2.2.3. Enzymology
Enzymes including amylase, lipase, ALT and AST were deter-
mined terminally. For enzymes determination, animals were
anesthetized with ketamine (100 mg/kg) (Ali et al., 2013),
700 R. Shah et al.blood was collected by cardiac puncture, centrifuged, and the
serum collected was stored at 4–8 C which was then analyzed
for the levels of enzymes using spectrophotometer (Unico
1100RS).
2.2.4. Body weight measurement
The animals were weighed before the administration of ﬁrst
dose as well as weekly before the administration of next newly
calculated dose. The percent weight gain was calculated by
using the following formula.
Percent gain in bodyweight¼100weight ðgÞon respective week
Weight ðgÞon zeroweeks
ð1Þ1500
Control
Olanzapine (5, 10 & 15mg/kg/d)2.3. Histological study
2.3.1. Hemotoxylin and Eosin (H & E) staining
The animals were sacriﬁced, selected tissues isolated, washed
with phosphate buffered saline (PBS) and ﬁxed in neutral buf-
fered formalin (NBF) for not less than 6 h. The ﬁxed samples
of tissues were sliced into small pieces of 3–5 mm and embed-
ded separately in parafﬁn blocks. These blocks were sectioned
using microtome (SLEE MAINZ, CUT 5062). Sections of dif-
ferent sizes (5 lm and/or 10 lm) were taken and stained using
H & E staining technique. The stained slides were analyzed
under a light microscope (LABOMED LX400) equipped with
camera (iVu 3100). The images obtained were labeled, saved
and interpreted for any drug induced changes (Ali et al., 2013).
2.4. Statistical analysis
Data were expressed as mean ± standard error of the mean
(SEM). The signiﬁcance of difference among mean values
was analyzed either by one way ANOVA followed by
Bonferroni’s multiple comparison test or by unpaired t-test
using GraphPad Prism 5 (Graph Pad Software Inc. San
Diego CA, USA).0
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Figure A.1 Effect of olanzapine on random blood sugar (RBS):
Olanzapine was orally administered to male rats (n= 7) at a dose
of 5 mg/kg/d for the ﬁrst eight weeks, which was increased to
10 mg/kg/d in the next four weeks and then to 15 mg/kg/d in the
last two weeks. (ANOVA followed by Bonferroni’s Multiple
Comparison Test) (**P< 0.01, ***P< 0.001).3. Results
3.1. Random blood sugar
Random blood sugar (RBS) was determined on a weekly basis.
Olanzapine showed a signiﬁcant rise in blood sugar in the 8th
to 14th weeks of the experiment (*P< 0.05, **P< 0.01,
***P< 0.001, Fig. A.1).
3.2. Pancreatic Function Tests (PFTs) and Liver Function Tests
(LFTs)
Olanzapine treatment showed a signiﬁcant rise in amylase
(*P< 0.05) and lipase levels (***P< 0.001). Olanzapine
showed no signiﬁcant change in ALT and AST levels
(P> 0.05) (Fig. A.2).
3.3. Percent weight gain
Olanzapine treatment showed signiﬁcant percent weight gain
in controls as compared to olanzapine treated group in the
5th week of ﬁrst 8 weeks treatment (*P< 0.05, **P< 0.01,
**P< 0.001) (5 mg/kg/d), in the next 4 weeks treatment
(***P< 0.001) (10 mg/kg/d) and in the last 2 weeks treatment
(15 mg/kg/d) (***P< 0.001). Nonetheless, the animals treated
with saline showed normal growth pattern (Fig. A.3).
3.4. Histological results
3.4.1. Effect on pancreas
As depicted in Fig. A.4, chronic treatment with olanzapine
induced pathological changes in pancreas, including derange-
ment of beta cells and ﬁbrotic growth. The exocrine portion
remained unaffected.0
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Figure A.2 Effect of olanzapine on enzymes: Olanzapine was
administered orally to male rats (n= 7) at a dose of 5 mg/kg/d for
the ﬁrst eight weeks, which was increased to 10 mg/kg/d in the
next four weeks and then to 15 mg/kg/d in the last two weeks,
which showed a signiﬁcant increase in amylase (U/L) (*P< 0.05)
and lipase (***P< 0.001) levels (U/L) compared to controls
treated with acidiﬁed N/S. The same treatment did not cause any
change in the levels of alanine and aspartate transaminases
(P> 0.05). (unpaired t-test).
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Figure A.3 Effect of olanzapine on body weight: Olanzapine was
orally administered to male rats (n= 7) at a dose of 5 mg/kg/d for
the ﬁrst eight weeks, which was increased to 10 mg/kg/d in the
next four weeks and then to 15 mg/kg/d in the last two weeks. The
signiﬁcant percent weight gain was observed in controls as
compared to olanzapine treated group. (ANOVA followed by
Bonferroni’s Multiple Comparison Test). (*P< 0.05, **P< 0.01,
***P< 0.001).
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Our study revealed normal parenchyma of liver showing no
prominent drug induced changes. The center of lobules
revealed central vein with thin walls and hepatic portal triad
composed of a single portal vein, an artery and the bile ductIntercalated duct Blood vessel
Islet of Langerhans
Blood vessels
Serous acini & zymogenic cells
Islets of Lang
A1 B
A2 B
Figure A.4 Olanzapine induced histopathological changes in the
magniﬁcations): Photomicrographs of a section (5 lm) of pancreas from
kg/d for the ﬁrst eight weeks, 10 mg/kg/d in next four weeks and 15 mg/
islet of Langerhans interspersed among the pancreatic exocrine acini.
cells. The olanzapine treated pancreas showed nodular appearance of is
cells.at the periphery. Hepatic plates composed of hepatocytes were
arranged in an interanastomosing network of single cell thick
trabeculae separated by vascular channels/sinusoids forming
hexagonal structures with central vein (Fig. A.5).
3.4.3. Effect on kidneys
As depicted in Fig. A.6, a mild to moderate focal increase in
glomerular cellularity and cellular proliferation were observed
in the kidneys. A few glomerular capsules with negligible base-
ment membranes could be identiﬁed.4. Discussion
The previous studies show inconsistent ﬁndings about weight
gain and hyperglycemia (Baptista et al., 1987). Weight gain
has been very serious issue frequently and controversially
reported with olanzapine and other APDs (Arjonaa et al.,
2004; Gohlke et al., 2012; Wirshing et al., 1998). In this study,
signiﬁcant weight loss was observed with olanzapine that is not
in line with most of the studies reported in humans where such
treatment has shown weight gain, however, there are also
reports that male rats have shown no or little change in weight
with an oral dose of 5 mg/kg/d (Pouzet et al., 2003). Several
mechanisms of olanzapine have been postulated, including its
antagonistic effect on D2, 5-HT2C, a1, a2, H1 and M3 recep-
tors, but still no decisive conclusion has been elucidated about
the mechanisms of its toxicities. Some authors have correlated
the weight gain with leptin and/or ghrelin, which cause hyper-
phagia (Arjonaa et al., 2004; Baptista et al., 1987; Cope et al.,
2005; Sentissi Othman et al., 2008). In addition to weight lossIslet of Langerhans
Interlobular connective tissue septa
Blood vessel
Fibrotic growth
erhans
1
2
pancreas (H & E; A1, B1; 100· and A2, B2; 400· original
a rat treated with normal saline (A1 and A2) or olanzapine (5 mg/
kg/d in the last two weeks). The saline treated pancreas showed the
The exocrine component consisted of serous acini and zymogenic
let of Langerhans due to ﬁbrotic growth with derangement of beta
C1
C2
D1
D2
Central vein
Hepatic Plates
Portal vein
Hepatic artery
Bile duct
Hepatocyte with 
prominent nucleus
Central vein
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Bile duct
Figure A.5 Olanzapine induced histopathological changes in the liver (H & E; C1, D1; 100· and C2, D2; 400· original magniﬁcations):
Photomicrographs of a transverse section (5 lm) of liver of rats treated for 14 weeks with normal saline (C1 & C2) or olanzapine (5 mg/kg/
d for the ﬁrst eight weeks, 10 mg/kg/d in next four weeks and 15 mg/kg/d in the last two weeks) (D1 & D2), showing normal cellular
architecture. The center of lobules revealed center thin walled vein with portal triad containing single portal vein, an artery and the bile
duct at the periphery. Hepatocytes were arranged in an interanastomosing network of single cell thick trabeculae separated by vascular
channels/sinusoids forming hexagonal structures with central vein and radiating hepatocytes trabeculae.
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Figure A.6 Olanzapine induced histopathological changes in the kidneys (H & E; E1, F1; 100· and E2, F2; 400· original
magniﬁcations): Photomicrographs of a section (5 lm) of the kidneys of rats treated with normal saline (E1 & E2) or olanzapine (5 mg/kg/
d for the ﬁrst eight weeks, 10 mg/kg/d in next four weeks and 15 mg/kg/d in the last two weeks) (F1 & F2), showing mild to moderate focal
increase in glomerular cellularity and cellular proliferation. A few glomerular capsules with negligible basement membranes could be
identiﬁed.
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Olanzapine induced biochemical and histopathological changes 703in this study, olanzapine showed signiﬁcant effects on blood
glucose level, but much later in the 8th week of the study, when
treated orally for an extended period of time, still the rise in
blood sugar is much lower than the previous studies in animal
models having free access to food.
Until now the scientists have tried to elucidate the mecha-
nism of toxicities associated with olanzapine, but no or very
little attention has been paid to correlate the alterations in bio-
chemistry with histology of the affected organs. There are rare
reports on hepatotoxicity and nephrotoxicity but no study on
pancreatic toxicity has been found. Therefore the novelty of
this study is the simultaneous correlation of both biochemistry
and histology of pancreas and liver. Likewise, the drug caused
rise in blood sugar, rise in amylase and lipase as well as an
insult to the architecture of the pancreas, including derange-
ment of beta cells and ﬁbrotic growth in the islet of
Langerhans. The damage could be more severe if exposure
to drug would continue and free access to food allowed. The
damage could be due to blockade of muscarinic M3 receptors
since studies have discovered that the binding afﬁnity of sec-
ond generation antipsychotics to the M3 receptors is a predic-
tor of diabetes risk. Second generation antipsychotics-induced
insulin dysregulation may be partly due to blockade of central
and peripheral muscarinic M3 receptors, causing an initial dis-
ruption to insulin secretion and glucose homeostasis that can
progressively lead to insulin resistance and diabetes during
chronic treatment (Weston-Green et al., 2013). Olanzapine
alters the density of M3 receptors in discrete nuclei of the
hypothalamus and caudal brainstem, the regions that regulate
glucose homeostasis and insulin secretion through vagal inner-
vations of the pancreas (Weston-Green et al., 2013). The pan-
creas is innervated by adrenergic and cholinergic neurons,
which have an indirect effect on the release of insulin through
sympathetic and parasympathetic vagal stimulation. Time-
sensitive response of insulin to APDs has been reported that
is decrease in its level after acute exposure (14 days) to an
APD while increase in its level after chronic exposure accom-
panied with hyperglycemia, the later, reﬂects insulin resistance
(Chiu et al., 2010; Weston-Green et al., 2013). A cohort of
Taiwanese schizophrenics was examined for the effects of olan-
zapine on glucose-stimulated insulin response which showed
hypoinsulinemia in the ﬁrst two weeks of olanzapine treat-
ment, returned to baseline levels in the next two weeks and
then hyperinsulinemia in the next four weeks of treatment
(Chiu et al., 2010; Weston-Green et al., 2013). In addition to
previous hypothesis, hyperglycemia could be due to direct
damage to the pancreas especially the beta cells of islet of
Langerhans and oxidative stress that is reﬂected by derange-
ment of beta cells, ﬁbrotic growth in the pancreas and rise in
amylase and lipase levels in our study.
There exists a single study on olanzapine-induced hepato-
toxicity supplemented with the histopathological ﬁndings that
reported no damage to the general architecture of liver except
to hepatocytes at cellular level, using doses of 2 and 4 mg/kg/d
i.p for six weeks (Odaci et al., 2009). Liver enzymes elevation
has been, however, reported extensively, but asymptomatic
and returned to normal when the drug was discontinued
(Gonzalez-Heydrich et al., 2003; Ozcanli et al., 2006). On the
other hand, Gomez and colleagues studied more than 2000
patients treated with olanzapine who exhibited no symptoms
of jaundice or clinical hepatitis at six month follow-up
(Gomez et al., 2000).Similarly there are rare reports on olanzapine-induced
nephrotoxicity as well but with low dose (2.5 mg/kg/d) injected
intraperitoneally for 6 weeks, however the dose of 0.5 mg/kg/d
has been reported safe (Mustafa et al., 2012). Furthermore, we
found mild to moderate focal increase in glomerular cellular-
ity, cellular proliferation and Bowman’s capsules with negligi-
ble basement membranes.
The reasons of inconsistent ﬁndings with the previous stud-
ies could be due to various factors including (1): Male gender
(Pouzet et al., 2003), (2): Access to restricted diet (Gohlke
et al., 2012), (3): Chronic exposure to high dose of olanzapine
that could have developed resistance, (4): Once daily dosing
though with shorter half life of 2½ h (Van der Zwaal et al.,
2008), (5): Possible degradation of olanzapine in solution
before administration (Van der Zwaal et al., 2008), and (6):
Four month study is still shorter to induce pathological
changes in liver, since 2000 patients after six month follow-
up showed no hepatotoxicity (Gomez et al., 2000). Out of all
of the above postulations, the importance of restricted diet
cannot be ignored. Our results indicate that one may possibly
protect patients from the untoward effects by devising diet
with a calculated amount of calories during the course of treat-
ment with APDs. The effect of calories intake has also been
established by Fountain and his colleagues in healthy human
volunteers (Fountaine et al., 2010).
We consider it as an advancement in the major issues asso-
ciated with olanzapine which might be lessened with dietary
interventions, as predicted previously. Dietary interventions
would be more fruitful than anti-obesity drugs due to the con-
cerns of untoward effects. Not only weight gain, all other
alarming events such as dyslipidemia, cardiovascular risks
and hyperglycemia might be managed if restricted and bal-
anced diet is provided to the patients on antipsychotics. The
other very important aspects regarding weight in schizophren-
ics could be hypothesized that it is not the APDs that cause
weight gain and metabolic syndrome rather schizophrenia that
causes weight loss and metabolic abnormalities. The drug
might be hitting the same pathway(s) that would have been
reversed by the schizophrenia. This could be observed in clin-
ics/hospitals that the majority of the schizophrenics are under-
weight and unable to control pulse rate and blood pressure
which start improving with the use of APDs. Our study has
shown some positive expectations from the postulation of diet-
ary interventions in patients on antipsychotic therapy. But still
the risk of toxicity may not be ignored, as evident from patho-
logical changes in the architecture of kidneys and pancreas.
Since olanzapine has been the mainstay of treatment strategies
for schizophrenics and patients with other affective disorders,
it must be used with caution and regular monitoring of body
weight, renal functions, blood glucose, lipid proﬁle, amylase
and/or lipase shall be exercised, so that the risk to the patients
could be minimized. We suggest switching to other safe
antipsychotics when the patient’s previous condition is
improved with olanzapine. It may be restricted for use in reac-
tive and non-responding cases only and then switched to safer
drug when the previous symptoms are alleviated.5. Conclusion
The study helps us in concluding that olanzapine is compara-
tively safer to the liver, but may be toxic to pancreas and
704 R. Shah et al.kidneys. Furthermore, we found that the toxicities associated
with olanzapine might be lessened if the diet provided is inter-
vened, since our dietary intervention has delayed the already
reported events for weeks. Based on this study and the pub-
lished reports, it is suggested to monitor body weight, blood
glucose, LFTs, RFTs, lipid proﬁle and amylase and/or lipase
in patients undergoing therapy with olanzapine.
6. Limitations
LFTs, amylase, lipase and histological examinations were done
terminally which could not be correlated with the doses being
used. Further, histopathological ﬁndings of kidneys were not
supplemented with RFTs.
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